IntelliPharmaCeutics


Analyst Sees Over 160% Upside for IntelliPharmaCeutics Intl Inc (USA) Stock

It can be tricky putting a price tag on a biotech company, especially one that offers no profits but promises of big success …

Stock Update (NASDAQ:IPCI): IntelliPharmaCeutics Announces First Quarter 2016 Results

Intellipharmaceutics International Inc. (NASDAQ:IPCI), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage …

Analysts are Bullish on IntelliPharmaceuticals Following Deal with Teva Pharmaceuticals

hares of IntelliPharmaceutics International  (NASDAQ: IPCI) saw a nearly 6% increase in trading on Tuesday, February 2nd following the company’s announcement that it has signed …

IPCI’s Novel Overdose Deterrence Technology Blows Us Away, Says Maxim

In a research report released September 5, Maxim Group analyst Jason Kolbert upgraded shares of IntelliPharmaCeutics (NASDAQ:IPCI) from Hold to Buy rating and raised his price target to $7.00 (from $3.

IntelliPharmaCeutics: We See No Reason To Be Long On Shares, Says Maxim

In a research report released July 21, Maxim Group analyst Jason Kolbert reaffirmed a Hold rating on IntelliPharmaCeutics (IPCI) with a $3 price target.  The analyst commented: “IPCI reported the quarter last …

Maxim Group Downgrades Intellipharmaceutics To Hold, Lowers PT to $3

In a research report issued today, IntelliPharmaCeutics International Inc. (IPCI) was downgraded by analyst Jason Kolbert at Maxim Group from Buy to Hold.